

1 **Title Page:**

2 **Reverse transcription loop-mediated isothermal amplification combined with**  
3 **nanoparticles-based biosensor for diagnosis of COVID-19**

4

5 Xiong Zhu <sup>1,\*</sup>, Xiaoxia Wang <sup>1,\*</sup>, Limei Han <sup>1</sup>, Ting Chen <sup>1</sup>, Licheng Wang <sup>1</sup>, Huan Li <sup>1</sup>,  
6 Sha Li <sup>1</sup>, Lvfen He <sup>1</sup>, Xiaoying Fu <sup>1</sup>, Shaojin Chen <sup>1</sup>, Mei Xing <sup>4</sup>, Hai Chen <sup>1</sup> and Yi  
7 Wang <sup>2,3,†</sup>

8 <sup>1</sup> Central & Clinical Laboratory of Sanya People's Hospital, Sanya, Hainan 572000,  
9 People's Republic of China.

10 <sup>2</sup> Department of Respiratory Disease, Beijing Pediatric Research Institute, Beijing  
11 Children's Hospital, Capital Medical University, National Center for Children's  
12 Health, Beijing 10045, P. R. China.

13 <sup>3</sup> Key Laboratory of Major Diseases in Children, Ministry of Education, Beijing Key  
14 Laboratory of Pediatric Respiratory Infection Disease, National Clinical Research  
15 Center for Respiratory Diseases, Beijing Children's Hospital, Capital Medical  
16 University, National Center for Children's Health, Beijing 10045, P. R. China.

17 <sup>4</sup> Wenchang People's Hospital, Sanya, Hainan 572000, P. R. China.

18 **Short title:** COVID-19 RT-LAMP-NBS assay

19 **Figure:** 6

20 **Tables:** 0

21 **Supplementary Materials:** 1

22 † Correspondence: **Yi Wang**

23 Department of Respiratory Infection Disease, Beijing Pediatric Research Institute,  
24 Beijing Children's Hospital, National Center for Children's Health, No. 56, Nanlishi  
25 Road, Xicheng District, Beijing 100045, China.

26 E-mail: [wildwolf0101@163.com](mailto:wildwolf0101@163.com)

27

28 \*These authors contributed equally to this article

## 29 **ABSTRACT**

30 Given the scale and rapid spread of severe acute respiratory syndrome coronavirus 2  
31 (SARS-CoV-2, known as 2019-nCov) infection (COVID-19), the ongoing global  
32 SARS-CoV-2 outbreak has become a huge public health issue. Rapid and precise  
33 diagnostic methods are thus immediately needed for diagnosing COVID-19,  
34 providing timely treatment and facilitating infection control. A one-step reverse  
35 transcription loop-mediated isothermal amplification (RT-LAMP) coupled with  
36 nanoparticles-based biosensor (NBS) assay (RT-LAMP-NBS) was successfully  
37 established for rapidly and accurately diagnosing COVID-19. A simple equipment  
38 (such as heating block) was required for maintaining a constant temperature (63°C)  
39 for only 40 min. Using two designed LAMP primer sets, F1ab (opening reading frame  
40 1a/b) and np (nucleoprotein) genes of SARS-CoV-2 were simultaneously amplified  
41 and detected in a 'one-step' and 'single-tube' reaction, and the detection results were  
42 easily interpreted by NBS. The sensitivity of SARS-CoV-2 RT-LAMP-NBS was 12  
43 copies (each of detection target) per reaction, and no cross-reactivity was generated  
44 from non-SARS-CoV-2 templates. Among clinically diagnosed COVID-19 patients,  
45 the analytical sensitivity of SARS-CoV-2 was 100% (33/33) in the oropharynx swab  
46 samples, and the assay's specificity was also 100% (96/96) when analyzed the clinical  
47 samples collected from non-COVID-19 patients. The total diagnosis test from sample  
48 collection to result interpretation only takes approximately 1 h. In sum, the  
49 RT-LAMP-NBS is a promising tool for diagnosing the current SARS-CoV-2  
50 infection in first line field, public health and clinical laboratories, especially for  
51 resource-challenged regions.

52 **KEYWORDS:** SARS-CoV-2; COVID-19; Rapid diagnosis; Reverse transcription  
53 loop-mediated isothermal amplification; Biosensor.

## 54 INTRODUCTION

55 In late December 2019, an unexpected outbreak caused by severe acute respiratory  
56 syndrome coronavirus 2 (SARS-CoV-2, known as 2019-nCov) emerged in Wuhan,  
57 Hubei province, China, which had previously not been reported in animals or humans  
58 (1). By press time, the novel coronavirus (SARS-CoV-2) has resulted in a huge  
59 epidemic in China and other 88 countries/territories, and there have been 98,129  
60 globally confirmed cases of SARS-CoV-2 infection (COVID-19), including 3, 380  
61 deaths (World Health Organization, COVID-19 Situation Report-46) (2). As the  
62 current outbreak of COVID-19 continues to evolve, COVID-19 has become a serious  
63 global health concern because of the possible fatal progression and rapidly growing  
64 numbers of new cases (3). Herein, it is urgently necessary to devise as many specific  
65 detection assays as possible to provide early, rapid and reliable diagnosis of  
66 COVID-19.

67 Diagnosis of COVID-19 based on clinical symptoms, especially in the early  
68 stages of this disease, is extremely difficult as there are no characteristic initial  
69 manifestations of COVID-19 (4). Although genome sequencing had high accuracy for  
70 diagnose of COVID-19, it was not applicable in rapid diagnosis for clinical  
71 large-samples because of its longer sequencing time and high requirements for  
72 experimental equipment (5). In the current outbreak of COVID-19, real-time reverse  
73 transcription polymerase chain reaction (rRT-PCR) was employed to detect  
74 SARS-CoV-2 in public health and clinical laboratories because it a specific and  
75 sensitive diagnostic method for detection the novel coronavirus (6). However,  
76 rRT-PCR technique strongly relies on complex apparatus, skilled personnel and a  
77 stable power supply, the total run time of rRT-PCR test is several hours from the  
78 clinical specimens to result reporting. In particular, some regions where outbreaks of  
79 COVID-19 emerge usually do not provide sufficient infrastructure for good rRT-PCR  
80 diagnostic services, especially for field laboratories and resource-limited settings (7).  
81 Hence, there is an urgent requirement for easy-to-use, more rapid and simpler  
82 detection techniques for diagnosis of COVID-19.

83 Loop-mediated isothermal amplification (LAMP), which is the most popular

84 isothermal amplification assay, is able to offer a diagnostic testing option for this  
85 scenario (8). The details of LAMP mechanism have been described by previous  
86 publications (9). Using the LAMP-based protocols, nucleic acid amplification is  
87 conducted under isothermal conditions (e.g., in a heating block) with high efficiency,  
88 specificity and speed, eliminating the use of precision thermal cycler for thermal  
89 change (9, 10). The LAMP technique is highly specific, because recognition of target  
90 sequence by six or eight independent regions is required (11). Thus far, LAMP  
91 combined with reverse transcription assay (RT-LAMP) had been developed for the  
92 detection of multiple respiratory RNA viruses (e.g., influenza viruses, middle east  
93 respiratory syndrome and severe acute respiratory syndrome coronavirus) (12).  
94 Regarding these traits of LAMP technique, development of a LAMP-based assay for  
95 diagnosis of COVID-19 can overcome the shortcomings posed by rRT-PCR methods,  
96 and facilitates rapid diagnosis and surveillance of COVID-19.

97 Up to now, two informal published LAMP assays have been developed for  
98 diagnosis of COVID-19, and preliminarily evaluated using clinical or stimulated  
99 respiratory samples (13, 14). Unfortunately, only a genetic sequence (Open reading  
100 frame 1a/b; F1ab) was amplified and detected in the two systems, an unreliable  
101 diagnosis result may be obtained when the two COVID-19 LAMP assays detected a  
102 sample with high homology sequence of SARS-CoV-2 (e.g., bat severe acute  
103 respiratory syndrome-like coronavirus, GenBank KY417152.1). Traditional  
104 monitoring techniques (e.g., agarose gel electrophoresis, SYBR dyes and PH  
105 indicator), which were non-specific for COVID-19 LAMP products, were employed  
106 for confirming the two COVID-19 LAMP results. In addition, the electrophoresis is a  
107 time-consuming and tedious procedure, and the judgment of color change of reaction  
108 vessel by unaided eye is potentially subjective. Therefore, there is a continuous  
109 command for devising the new LAMP-based assays, which are capable of  
110 simultaneously detecting multiple targets of SARS-CoV-2, providing more rapid and  
111 objective result, and facilitating simpler diagnosis.

112 Here, a 'one-step' and 'one-tube' RT-LAMP coupled with nanoparticles-based  
113 biosensor (NBS) assay (RT-LAMP-NBS) was developed for diagnosis of COVID-19

114 (**Figure 1 and 2**). Two target sequences, including F1ab and nucleoprotein gene (np),  
115 were simultaneously amplified in an isothermal reaction, and detected in a test step.  
116 We will expound the basic COVID-19 RT-LAMP principle, optimize the reaction  
117 parameters (e.g., amplification temperature), and demonstrate its feasibility.

118

## 119 **RESULTS**

### 120 **COVID-19 RT-LAMP-NBS design**

121 In the LAMP system (**Figure 1**), FIP (forward inner primer) initiates the isothermal  
122 amplification, and the new strand derived from FIP primer was displaced by the F3  
123 (forward primer) synthesis (**Step 1**). Then, 2 primers, including BIP (backward inner  
124 prime) and B3 (backward primer), annealed to the newly produced strand (**Step 2**),  
125 and displacement enzyme (*Bst* 2.0) extended in tandem generating a dumb-bell form  
126 product (**Step 3**). Thus, the stem-loop stem product can server as the template for the  
127 second stage of the LAMP reaction (exponential amplification). The LB\* primer  
128 (backward loop primer), which was labeled with biotin at the 5' end, could anneal to a  
129 distinct product derived from the exponential LAMP reaction stage (**Step 4**). The LB\*  
130 product also severed as the template for next amplification by LF\* (forward loop  
131 primer), which was modified at the 5' end with hapten (**Step 5**). As a result, a  
132 double-labeled detectable product (LF\*/LB\* product) was formed, and one end of the  
133 LF\*/LB\* product was labeled with hapten, and the other end with biotin (**Step 6, 7**).  
134 One hapten is assigned to one primer set, which provide the possibility for multiplex  
135 LAMP detection.

136 A representative schematic of COVID-19 RT-LAMP-NBS assay were displayed  
137 in **Figure 2**. In the COVID-19 RT-LAMP system, fluorescein (FITC) was assigned to  
138 F1ab primer set, and digoxigenin (Dig) for np primer set. Hence, F1ab-LF\* and  
139 F1ab-LB\* primers were labeled at the 5' end with FITC and biotin, and np-LF\* and  
140 np-LB\* for Dig and biotin, respectively (**Figure 2A**). With the assistance of AMV  
141 (avian myeloblastosis virus reverse transcriptase), the RNA (SARS-CoV-2 template)  
142 was converted to cDNA, which acted as the material for subsequent LAMP  
143 amplification (**Figure 2B**). After 40 min at 63°C, F1ab-LAMP products were

144 simultaneously labeled with FITC and biotin, and np-LAMP products for Dig and  
145 biotin (**Figure 2C**).

146

#### 147 **The principle of NBS visualization of COVID-19 RT-LAMP results**

148 As shown in the **Figure 3**, the result readout of COVID-19 RT-LAMP assay was  
149 exhibited using the NBS. The details of NBS was shown **Figure 3A** (Seen in  
150 'Materials and Method' section). For visualization of COVID-19 RT-LAMP results  
151 using NBS, aliquots (0.5  $\mu$ l) of reaction mixtures were deposited into the sample  
152 region (**Figure 3B**, step 1), and an aliquot (80  $\mu$ l) running buffer then was deposited  
153 on the same region (**Figure 3B**, step 2). At the detection stage, running buffer moves  
154 along NBS through capillary action, and rehydrates the SA-DNPS immobilized in the  
155 conjugate pad. The end of F1ab-RT-LAMP products labeled with FITC was captured  
156 by the anti-FITC antibody located in TL1 region (Test line 1), and the end of  
157 np-RT-LAMP products with Dig was captured by anti-Dig antibody located in TL2  
158 region (Test line 2). The other ends of F1ab- and np-RT-LAMP products, labeled with  
159 biotin, bind streptavidin-conjugated color nanoparticles for visualization (**Figure 3B**,  
160 step 3). The excess streptavidin-conjugated color nanoparticles were captured by  
161 biotinylated bovine serum albumin immobilized in CL (Control line), which  
162 demonstrated the working condition of NBS (**Figure 3B**, step 3). The interpretation of  
163 the COVID-19 RT-LAMP results using NBS was shown in **Figure 3C**.

164

#### 165 **Confirmation and detection of F1ab-, np- and COVID-19 RT-LAMP products**

166 The positive vessels of F1ab-, np- and COVID-19 RT-MCDA assay were visualized  
167 as light green using VDR (Visual detection reagent), while the reaction tubes of  
168 negative and blank controls remained colorlessness (**Figure S1**, top row). Using NBS,  
169 TL1 and CL were observed on the detection region for positive F1ab-RT-LAMP  
170 results, and TL2 and CL for positive np-RT-LAMP results. TL1, TL2 and CL  
171 simultaneously appeared on the detection region of NBS for positive COVID-19  
172 RT-LAMP results. Only CL appeared on the analysis area of NBS for negative and  
173 blank controls of F1ab-, np- and COVID-19 RT-LAMP results (**Figure S1**, bottom

174 row). These results indicated that F1ab- and np-LAMP primer sets were available for  
175 establish the COVID-19 RT-LAMP NBS assay for rapid and reliable detection of  
176 SARS-CoV-2. The parameter of optimal temperature for COVID-19 RT-LAMP  
177 technique also was tested, and reaction temperature of 63°C was used for performing  
178 the COVID-19 RT-LAMP amplification (**Figure S2** and **S3**).

179

#### 180 **Sensitivity of COVID-19 RT-LAMP-NBS assay**

181 The COVID-19 RT-LAMP-NBS was able to detect down 12 copies (each of  
182 F1ab-plasmid and np-plasmid) (**Figure 4**). Two target genes were detected and  
183 identified in a one-tube reaction (**Figure 4A**). The COVID-19 RT-LAMP results  
184 using NBS were in consistent with turbidity and VDR detection (**Figure 4B** and **4C**),  
185 while traditional monitoring techniques (VDR and turbidity) could not facilitate  
186 multiplex analysis. Furthermore, the sensitivity of COVID-19 RT-LAMP-NBS assay  
187 was in conformity with F1ab- and np-RT-LAMP assay (**Figure 4, S4** and **S5**).

188 The optimal duration time of COVID-19 RT-LAMP-NBS assay at the isothermal  
189 stage also was determined, and the template level at the detection limit appeared three  
190 red lines (TL1, TL2 and CL) when the RT-LAMP reaction was carried out only 30  
191 min at 63°C (**Figure S6**). For the RNA template detection, a reverse transcription  
192 process (10 min) is essential, thus a COVID-19 RT-LAMP reaction time of 40 min  
193 was recommended for detection of clinical samples. Therefore, the whole diagnosis  
194 process of COVID-19 RT-LAMP-NBS, including sample collection (3 min), rapid  
195 RNA extraction (15 min), RT-LAMP reaction (40 min) and result interpretation (<2  
196 min), was finished approximately 1 h (**Figure 5**).

197

#### 198 **Specificity of RT-LAMP-NBS assay**

199 The positive COVID-19 RT-LAMP-NBS results were obtained only from positive  
200 controls (120 copies each of F1ab-plasmid and np-plasmid) (**Table S1**). The negative  
201 results were observed in all pathogens of non-SARS-CoV-2 (virus, bacteria and fungi),  
202 in which only a red band (CL) was observed in the biosensor detection regions,  
203 indicating no cross-reaction with non-SARS-CoV-2 templates (**Table S2**).

## 204 **Application of the RT-LAMP-NBS assay in clinical samples**

205 Of the total of 129 respiratory samples, which were initially analyzed using rRT-PCR  
206 in Sanya People's Hospital in 2020, were enrolled in this report. Particularly, only the  
207 RNA templates were used after rRT-PCR performance. Among all the enrolled  
208 COVID-19 patients (33), the sensitivity of COVID-19 RT-LAMP-NBS assay 100%  
209 (33/33). The specificity was 100% (96/96) for COVID-19 RT-LAMP-NBS assay  
210 among non-COVID-19 patients, which were diagnosed as having pneumonia with  
211 confirmed pathogen in clinical laboratory of SanYa People's Hospital. These  
212 preliminary results revealed that the proposed COVID-19 RT-LAMP-BS assay had a  
213 high sensitivity and specificity for diagnosis of SARS-CoV-2 infection.

214

## 215 **Discussion**

216 An ongoing epidemic by SARS-CoV-2, starting in last December 2019 in Wuhan,  
217 China, is a huge public health concern (15). As of today (9 March 2020), 98 129 total  
218 confirmed cases have been documented, with 80 711 cases in China and the  
219 remaining cases distributed other 88 countries/regions in every continent (WHO,  
220 COVID-19 Situation Report-46) (16). Hence, there has been an immediate  
221 requirement for early, rapid and reliable diagnostic tests in the current outbreak. Such  
222 detection techniques are required not only in these countries where SARS-CoV-2  
223 infection are spreading but also in countries/regions threatened by SARS-CoV-2  
224 infection, even in countries/regions where COVID-19 have not yet been emerged.

225 Here, we reported a novel LAMP-based test for simple, rapid and reliable  
226 diagnosis of COVID-19, name COVID-19 RT-LAMP-NBS. Our assay merged  
227 LAMP amplification, reverse transcription, multiplex analysis with  
228 nanoparticles-based biosensor, and facilitated the diagnosis of COVID-19 in a  
229 one-step, single-tube reaction. Only simple apparatus (e.g., a water bath or a heating  
230 block) were need to maintain a constant temperature (63°C) for 40 min. Compared  
231 with the developed COVID-19 RT-LAMP assays, the RT-LAMP results in this report  
232 were visually and objectively indicated by NBS, which was a simple and easy-to-use  
233 platform, avoiding the requirement of complex process (e.g., electrophoresis), special



234 reagents (e.g., PH indicator) and expensive instrument (e.g., real-time turbidity) (13,  
235 14). Total analysis procedure could be complete approximately 1 h, including sample  
236 collection (3 min), rapid RNA extraction (15 min), RT-LAMP reaction (40 min) and  
237 result interpretation (< 2 min). Considering these traits, COVID-19 RT-LAMP-NBS  
238 assay is a rapid, economical and technically simple method, offering a measure of  
239 practicality for field and clinical laboratories, especially for resource-challenged  
240 settings.

241 Two RT-LAMP primer sets, including F1ab-RT-LAMP and np-RT-LAMP  
242 primer sets, were specifically designed recognizing eight regions of target genes  
243 (**Figure 6**), guaranteeing the high specificity for SARS-CoV-2 detection. The data of  
244 analytical specificity revealed that no false-positive results were produced from  
245 non-SARS-CoV-2 templates, and positive results were obtained from positive control  
246 and SARS-CoV-2 templates (**Table S1**). Moreover, two targets (F1ab and np genes)  
247 could be simultaneously amplified and detected in a 'one-step' RT-LAMP reaction,  
248 which further guaranteed the assay's reliability. Thus, our approach could effectively  
249 avoid the undesired results yielded from the developed COVID-19 RT-LAMP assays  
250 that only amplified and detected a target gene (e.g., F1ab) (13, 14).

251 The data of analytical sensitivity validated that RT-LAMP-NBS assay is  
252 sufficiently sensitive for diagnosis of COVID-19. Us this protocol, detection limit of  
253 COVID-19 RT-LAMP-NBS was 12 copies each of F1ab-plasmid and np-plasmid,  
254 which is in conformity with assay's sensitivity generated from F1ab-RT-LAMP-NBS  
255 and N-RT-LAMP-NBS detection (**Figure 4, S4 and S5**). The COVID-19  
256 RT-LAMP-NBS assay did not improve or decrease the analytical sensitivity when  
257 compared with the signlex analysis (F1ab-RT-LAMP and np-RT-LAMP assays). In  
258 this report, we did not compare the sensitivity results obtained from COVID-19  
259 RT-LAMP-NBS with rRT-PCR assay, because the quality of commercially available  
260 test kits for SARS-CoV-2 detection remains uneven. These commercial rRT-PCR  
261 assays used in Sanya People's Hospital produce uninform results when they were  
262 applied to analyze the 10-fold diluted plasmid templates. For detection the RNA  
263 templates extracted from respiratory samples, 100% (33/33) of clinical samples

264 examined by rRT-PCR exhibited completely consistent diagnosis, and analytical  
265 specificity was also 100% (96/96) for COVID-19 RT-LAMP-NBS when analyzing  
266 the RNA templates from non-SARS-CoV-2 infection patients.

267

## 268 **Conclusion**

269 The one-step single-tube COVID-19 RT-LAMP-NBS assay devised in this report  
270 offers an attractive diagnosis tool for SARS-CoV-2 detection. The nearly  
271 equipment-free platform of COVID-19 RT-LAMP-NBS makes it applicable for  
272 resource-limited laboratories (e.g., field laboratories), and the diagnosis results are  
273 easy to interpret. The high specificity, sensitivity and feasibility of COVID-19  
274 RT-LAMP-NBS assay for detection of SARS-CoV-2, and its low cost and ease of use  
275 make the target assay a valuable diagnosis tool for use in field, clinic, public health  
276 and primary care laboratories, especially for resource-poor regions.

277

## 278 **Materials and Methods**

### 279 **Construction of nanoparticles-based biosensor (NBS)**

280 As shown in **Figure 3A**, NBS contains four components (a sample pad, a conjugate  
281 pad, a nitrocellulose membrane and an absorbent pad) (Jie-Yi Biotechnology). Rabbit  
282 anti-fluorescein antibody (anti-FITC, 0.2 mg/ml, Abcam. Co., Ltd.), sheep  
283 anti-digoxigenin antibody (Anti-Dig, 0.25 mg/mL, Abcam. Co., Ltd.) and biotinylated  
284 bovine serum albumin (biotin-BSA, 4 mg/mL, Abcam. Co., Ltd.) were immobilized at  
285 detection regions (nitrocellulose membrane, NC) as the test line 1 (TL1), test line 2  
286 (TL2) and control line (CL), respectively, with each line separated by 5 mm. Dye  
287 streptavidin coated polymer nanoparticles (SA-DNPs, 129 nm, 10mg mL<sup>-1</sup>, 100mM  
288 borate, pH 8.5 with 0.1% BSA, 0.05% Tween 20 and 10mM EDTA) were  
289 immobilized at the conjugated regions. Thus, the NBS devised here can detect three  
290 targets (a chromatography control and two target amplicons). The assembled NBS  
291 were cut into 4-mm dipsticks, and dryly stored at the room temperature until use.

292

### 293 **Primer design**

294 Two RT-LAMP primer sets (F1ab-RT-LAMP and np-RT-LAMP) were designed  
295 according the LAMP mechanism using a specialized software (PrimerExplore V5),  
296 which targeted F1ab and np gene of SARS-CoV-2 (GenBank MN908947,  
297 Wuhan-Hu-1) (**Figure 6**). Then, a Blast analysis of the GenBank nucleotide database  
298 was performed for the F1ab- and np-LAMP primers to validate sequence specificity.  
299 The more details of primer design, locations, sequences and modifications were  
300 shown in **Figure 6** and **Table S2**. All of the oligomers were synthesized and purified  
301 by RuiBo Biotech. Co., Ltd. (Beijing, China) at HPLC purification grade.

302

### 303 **Reverse transcription LAMP reaction (RT-LAMP)**

304 The conventional RT-LAMP (F1ab- and np-RT-LAMP) was carried out in a one-step  
305 reaction in a 25- $\mu$ l mixture containing 12.5  $\mu$ l 2 $\times$ isothermal reaction buffer [40 mM  
306 Tris-HCl (pH 8.8), 40 mM KCl, 16 mM MgSO<sub>4</sub>, 20 mM (NH<sub>4</sub>)<sub>2</sub>SO<sub>4</sub>, 2 M betaine and  
307 0.2 % Tween-20], 8 U of Bst 2.0 DNA polymerase (New England Biolabs), 5 U of the  
308 avian myeloblastosis virus reverse transcriptase (Invitrogen), 1.4 mM dATP, 1.4 mM  
309 dCTP, 1.4 mM dGTP, 1.4 mM dTTP, 0.4  $\mu$ M each of F3 and B3, 0.4  $\mu$ M each of LF,  
310 LF\*, LB and LB\*, 1.6  $\mu$ M each of FIP and BIP and template (1 $\mu$ l for the standard  
311 plasmid).

312 The COVID-19 RT-LAMP was also performed in a one-step reaction in a 25- $\mu$ l  
313 mixture containing 12.5  $\mu$ l 2 $\times$ isothermal reaction buffer [40 mM Tris-HCl (pH 8.8),  
314 40 mM KCl, 16 mM MgSO<sub>4</sub>, 20 mM (NH<sub>4</sub>)<sub>2</sub>SO<sub>4</sub>, 2 M betaine and 0.2 % Tween-20],  
315 8 U of Bst 2.0 DNA polymerase (New England Biolabs), 5 U of the avian  
316 myeloblastosis virus reverse transcriptase (Invitrogen), 1.4 mM dATP, 1.4 mM dCTP,  
317 1.4 mM dGTP, 1.4 mM dTTP, 0.25  $\mu$ M each of F1ab-F3 and F1ab-B3, 0.25  $\mu$ M each  
318 of F1ab-LF, F1ab-LF\*, F1ab-LB and F1ab-LB\*, 1.0  $\mu$ M each of F1ab-FIP and  
319 F1ab-BIP, 0.15  $\mu$ M each of np-F3 and np-B3, 0.15  $\mu$ M each of np-LF, np-LF\*, np-LB  
320 and np-LB\*, 0.6  $\mu$ M each of np-FIP and np-BIP and template (1 $\mu$ l for the each  
321 standard plasmid, 5 $\mu$ l for samples).

322 The monitoring techniques, including real-time turbidity (LA-320C), visual  
323 detection reagents (VDR) and NBS, were employed for confirming the RT-LAMP

324 reactions and optimizing the reaction parameters (e.g., reaction temperature and  
325 isothermal time).

326

### 327 **Sensitivity of the RT-LAMP-NBS assay**

328 Two standard plasmids (F1ab-plasmid and np-plasmid) were commercially  
329 constructed by Tianyi-Huiyuan Biotech. Co., Ltd. (Beijing, China), which contain the  
330 F1ab and np sequences, respectively. Ten-fold serial dilutions ( $1.2 \times 10^4$  to  $1.2 \times 10^{-2}$   
331 copies) of F1ab-plasmid and np-plasmid were used to evaluate assay's sensitivity. The  
332 plasmid concentration at detection limit level was employed for testing the duration  
333 time required by COVID-19 RT-LAMP-NBS assay.

334

### 335 **Specificity of the COVID-19 RT-LAMP-NBS assay**

336 The specificity of the COVID-19 RT-LAMP-NBS assay was examined by detecting  
337 the templates extracted from various pathogens, including viruses, bacteria and fungi  
338 (**Table S1**).

339

### 340 **Feasibility of COVID-19 RT-LAMP-NBS using clinical samples**

341 Respiratory samples were collected from COVID-19 infection patients in SanYa  
342 People's Hospital, Hainan, which were defined according to standard diagnosis and  
343 treatment criteria of COVID-19 (Trial Version 6). The RNA templates extracted from  
344 respiratory samples were used after clinical and laboratory diagnosis, which was  
345 conducted using the RT-qPCR kit (Recommended by the China CDC). Collection of  
346 these RNA templates and analysis of them were approved by SanYa People's Hospital.  
347 5  $\mu$ l RNA was used as templates for performing the COVID-19 RT-LAMP-NBS test.

348

349 **Contributors:** Yi Wang and Xiong Zhu conceived and designed this study. Xiong Zhu, Xiaoxia  
350 Wang, Licheng Wang, Limei Han, Huan Li, Ting Chen, Shaojin Chen, Mei Xing, Hai Chen and Yi  
351 Wang performed the experiments. Xiaoxia Wang, Xiong Zhu and Yi Wang analyze the data. Xiong  
352 Zhu, Xiaoxia Wang and Yi Wang contributed the reagents and analysis tools. Xiong Zhu, Xiaoxia  
353 Wang, Licheng Wang, Limei Han, Huan Li, Ting Chen, Shaojin Chen, Mei Xing and Hai Chen  
354 contributed the materials. Yi Wang conducted the software. Xiong Zhu and Xiaoxia Wang drafted the  
355 manuscript. Xiong Zhu and Yi Wang revised the manuscript.

356 **Funding:** This work was supported by grants from the Key Research and Development Program of  
357 Hainan Province (ZDYF2019149, ZDYF2017163), and Youth Science Foundation of Natural Science  
358 Fund of Hainan Province (818QN326).

359 **Competing interests:** The authors declare that they have no competing interests.

360 **Ethical approval:** This study was approved by the Ethics Committee of the Sanya People's Hospital  
361 (SYPH-2019(41)-2020-03-06).

362 **Data sharing:** No additional data available.

363 **Transparency declaration:** The lead author and guarantor affirms that the manuscript is an honest,  
364 accurate, and transparent account of the study being reported; that no important aspects of the study  
365 have been omitted; and that any discrepancies from the study as planned and registered have been  
366 explained.

367

## 368 Reference

- 369 1. X.-W. Xu *et al.*, Clinical findings in a group of patients infected with the 2019 novel  
370 coronavirus (SARS-Cov-2) outside of Wuhan, China: retrospective case series. *Bmj*  
371 **368**, (2020).
- 372 2. R. Lu *et al.*, Genomic characterisation and epidemiology of 2019 novel coronavirus:  
373 implications for virus origins and receptor binding. *The Lancet* **395**, 565 (2020).
- 374 3. C. Wang, P. W. Horby, F. G. Hayden, G. F. Gao, A novel coronavirus outbreak of  
375 global health concern. *The Lancet* **395**, 470 (2020).
- 376 4. C. Huang *et al.*, Clinical features of patients infected with 2019 novel coronavirus in  
377 Wuhan, China. *The Lancet* **395**, 497 (2020).
- 378 5. F. Wu *et al.*, A new coronavirus associated with human respiratory disease in China.  
379 *Nature*, 1 (2020).
- 380 6. V. M. Corman *et al.*, Detection of 2019 novel coronavirus (2019-nCoV) by real-time  
381 RT-PCR. *Eurosurveillance* **25**, (2020).
- 382 7. D. K. Chu *et al.*, Molecular diagnosis of a novel coronavirus (2019-nCoV) causing an  
383 outbreak of pneumonia. *Clinical chemistry*, (2020).
- 384 8. Y. Wang *et al.*, Loop-mediated isothermal amplification label-based gold nanoparticles  
385 lateral flow biosensor for detection of *Enterococcus faecalis* and *Staphylococcus*  
386 *aureus*. *Frontiers in microbiology* **8**, 192 (2017).
- 387 9. G. A. Obande, K. K. B. Singh, Current and Future Perspectives on Isothermal Nucleic  
388 Acid Amplification Technologies for Diagnosing Infections. *Infection and Drug*  
389 *Resistance* **13**, 455 (2020).
- 390 10. N. G. Schoepp *et al.*, Rapid pathogen-specific phenotypic antibiotic susceptibility  
391 testing using digital LAMP quantification in clinical samples. *Science Translational*  
392 *Medicine* **9**, eaal3693 (2017).
- 393 11. N. Chotiwan *et al.*, Rapid and specific detection of Asian-and African-lineage Zika  
394 viruses. *Science translational medicine* **9**, eaag0538 (2017).
- 395 12. Y. P. Wong, S. Othman, Y. L. Lau, S. Radu, H. Y. Chee, Loop-mediated isothermal  
396 amplification (LAMP): a versatile technique for detection of micro-organisms. *Journal*  
397 *of applied microbiology* **124**, 626 (2018).
- 398 13. L. E. Lamb, S. N. Bartolone, E. Ward, M. B. Chancellor, Rapid Detection of Novel  
399 Coronavirus (COVID19) by Reverse Transcription-Loop-Mediated Isothermal  
400 Amplification. *Available at SSRN 3539654*, (2020).
- 401 14. L. Yu *et al.*, Rapid colorimetric detection of COVID-19 coronavirus using a reverse  
402 tran-scriptional loop-mediated isothermal amplification (RT-LAMP) diagnostic  
403 plat-form: iLACO. *medRxiv*, (2020).
- 404 15. D. L. Heymann, N. Shindo, COVID-19: what is next for public health? *The Lancet*,  
405 (2020).
- 406 16. Q. Liu *et al.*, Assessing the Tendency of 2019-nCoV (COVID-19) Outbreak in China.  
407 *medRxiv*, (2020).


408

409

410 **Figure legends**

411

412



413


414

**Figure 1. Outline of LAMP assay**

415 **Top row**, outline of LAMP with LF\* and LB\*; **Bottom row**, schematic depiction of  
 416 the new forward/backward loop primer (LF\*/LB\*). LF\* was labeled with hapten at  
 417 the 5' end, and LB\* was labeled with biotin at the 5' end.

418

419



420

421

**Figure 2. Mechanistic description of the COVID-19 RT-LAMP-NBS assay**

422

(A), Preparing the amplification mixtures. (B), RT-LAMP reaction. (C), The

423

detectable COVID-19 RT-LAMP products were formed. F1ab-RT-LAMP products

424

were simultaneously labeled with FITC and biotin, and np-RT-LAMP labeled with


425

Dig and biotin.



426

427




428

429 **Figure 3. The principle of NBS for visualization of COVID-19 RT-LAMP**  
430 **products**

431 (A), The details of NBS. (B), The principle of NBS for COVID-19 RT-LAMP  
432 products. (C), Interpretation of the COVID-19 RT-LAMP results. I, a positive result for F1ab and np (TL1, TL2 and CL appear on the NBS); II, a positive result for N  
433 (TL2 and CL appear on the detection region); III, a positive result for F1ab (TL1 and  
434 CL appear on the detection region); IV, negative (only the control line appears on the  
435 NBS).  
436

437

438



439

440

**Figure 4. Sensitivity of COVID-19 RT-LAMP-NBS assay**

441 **A**, NBS applied for reporting the results; **B**, Real-time turbidity applied for reporting

442 the results; **C**, VDR applied for reporting the results. NBS (**A**)/Signals (**B**)/Tubes (**C**)

443 1-8 represented the plasmid levels (each of Flab-plasmid and np-plasmid) of  $1.2 \times 10^4$ ,

444  $1.2 \times 10^3$ ,  $1.2 \times 10^2$ ,  $1.2 \times 10^1$ ,  $1.2 \times 10^0$ ,  $1.2 \times 10^{-1}$ ,  $1.2 \times 10^{-2}$  copies per reaction and blank

445 control (DW). The plasmid levels of  $1.2 \times 10^4$  to  $1.2 \times 10^1$  copies per reaction produced

446 the positive reactions.

